Rapamycin · safety
Rapamycin side effects: what the dose actually changes
Most published rapamycin side effects come from patients dosing every day for years, while the longest placebo-controlled trial of weekly dosing ran 48 weeks. Those are two different lists, and most numbers in circulation come from the first.
Are longevity-dose side effects the same as transplant side effects?
No: the rapamycin side effects on the label come from daily transplant dosing, while weekly low-dose trials have run at most 48 weeks.[1] Sirolimus was approved in 1999 to stop kidney rejection, and oncology adds everolimus dosed near the tolerated ceiling.[2]
Longevity dosing is a different schedule: one weekly dose with six days of washout, meant to block the drug's main target briefly while its second, insulin-related complex recovers. Sustained inhibition of that second complex is thought to drive much of the insulin resistance, so the intermittent schedule is the whole design.[3]
Why the schedule, not just the milligrams, matters
The underlying biochemistry is well described: rapamycin acutely inhibits the drug's main target complex, whereas chronic exposure can also inhibit the second one.[10] A daily regimen keeps exposure continuous, which is the condition under which the second complex is blocked too. Daily and weekly dosing are therefore not bigger and smaller versions of one treatment.
What happens if you take rapamycin every day?
Strong human evidence Chronic use of rapamycin or everolimus is associated with mucosal ulcers, impaired wound healing and increased infection risk.[4] The metabolic cluster is equally consistent: raised triglycerides and cholesterol, insulin resistance and new-onset diabetes. Blood counts fall, and non-infectious pneumonitis is uncommon but watched for hardest.
None of that should be minimized. What should be questioned is whether it transfers. A cream is a different formulation with far lower blood levels, covered under rapamycin applied to skin.
The oncology dose ceiling
A dose-finding study in adults with solid tumors set the maximum tolerated daily oral dose of rapamycin at 6 mg.[2] At that level, hyperglycemia, hyperlipidemia and elevated liver enzymes each affected at least 20% of patients.
| Setting | Schedule | Total in one week |
|---|---|---|
| Oncology maximum tolerated dose | 6 mg every day | 42 mg |
| Most common longevity dose | 6 mg once a week (Lee et al. 2024) | 6 mg |
Hold that number next to longevity practice. A 2024 systematic review found 6 mg once a week among the most common off-label regimens in humans.[11] The tablet count matches; the weekly exposure is one seventh.
Why does rapamycin cause mouth ulcers?
Because the oral lining renews fast and mTORC1 drives that renewal. Stomatitis appears earliest and most often across every mTOR inhibitor and dose level, as a pooled analysis of seven phase 3 everolimus trials established.[5] Inhibiting mTORC1 slows repair of ordinary daily damage.
Show the numbers as a table
| Measure | Value |
|---|---|
| Solid tumors, any grade | 67% |
| Tuberous sclerosis | 70% |
| Of those: first sore by week 8 | 89% |
It is also the effect most reported on weekly dosing, which confirms the drug is pharmacologically active there. The usual response is a longer interval or smaller dose, a prescriber's call rather than a self-adjustment.
When does the first mouth sore usually show up?
Usually in the first weeks: across seven phase 3 trials in solid-tumor and tuberous sclerosis patients, most first stomatitis episodes arrived early and were low grade (per Rugo et al., 2016). For a reader starting treatment, a sore in the opening weeks is an expected sign of mTOR inhibition, not proof something has gone wrong.
No trial has measured stomatitis incidence at weekly low-dose rapamycin; the rate there is unknown, so a sore that recurs every cycle is worth raising with the prescriber.
- What this does not say
- Daily cancer-dose everolimus, far above weekly longevity doses of rapamycin. No trial has measured stomatitis incidence at weekly low-dose rapamycin (the 48-week PEARL trial of 5 or 10 mg weekly reports adverse events only as group totals); the rate there is unknown.
The only estimate at weekly doses comes from what people using the drug report, not from a controlled trial, so treat the figure below as a rough practitioner estimate.
About 15% of people taking rapamycin 6 mg once a week will develop mouth sores.
What did the low-dose human trials actually measure?
Early / mixed evidence Tolerability, not lifespan: PEARL, the longest placebo-controlled look at weekly dosing in healthy adults, ran 48 weeks at 5 mg and 10 mg with adverse events broadly comparable to placebo.[6] The trial was small and did not measure lifespan or disease incidence.
Show the numbers as a table
| When | Event | Detail |
|---|---|---|
| 1999 | Transplant approval | Daily dosing |
| 2014 | Vaccine trial | Short low-dose course |
| 2016 | Ulcer pooled analysis | Seven phase 3 trials |
| 2018 | Trial in over-70s | 1 mg daily, 8 weeks |
| 2025 | PEARL trial | Weekly dosing, 48 weeks |
The PEARL caveat
The PEARL authors were employed by AgelessRx, a company that prescribes the drug, which is a conflict worth weighing alongside the result.[6] The trial also found no change in visceral fat, one of the healthspan measures it tracked. A tolerable 48-week result in a sponsor-linked trial is a reason to keep testing, not a reason to stop monitoring.
The trial in adults over 70
A trial of 1 mg daily in adults aged 70 to 95 found significant declines in hemoglobin and red cell indices over eight weeks.[7] Nobody was clinically affected, but the change was invisible without a blood test, even at a dose described as trivially low.
Does low-dose rapamycin weaken the immune system?
Not in the 2 trials that tested it: randomized studies in older adults found brief low-dose exposure improved influenza vaccine response and, in the larger follow-up, reduced reported infections.[8] [9] The proposed explanation is that transient inhibition reverses some age-related immune exhaustion.
Treat that as interesting, not settled. Both used short courses of an analogue, and neither could detect rare infections. So low dose rapamycin side effects on immunity are neither the certainty the transplant label implies nor the non-issue enthusiasts claim.
How long do rapamycin side effects take to appear?
Mouth ulcers and blood count changes surface within about 8 weeks, while lipid and glucose effects are unmeasured beyond 48 weeks at weekly doses. The order below is the order in which each one tends to become visible, which is not the order in which each one matters.
| Effect | When it becomes visible | How it is noticed |
|---|---|---|
| Mouth ulcers | 89% of first episodes within 8 weeks (Rugo 2016) | Felt |
| Red cell indices | Within 8 weeks at 1 mg daily (Kraig 2018) | Blood test only |
| Lipids and glucose | Unmeasured beyond 48 weeks at weekly doses (PEARL) | Blood test only |
Mouth ulcers: the first weeks
In the pooled everolimus trials, 89% of first stomatitis episodes appeared within 8 weeks, and most were grade 1 or 2.[5] An early sore fits the expected pattern, while one that first appears months into a stable schedule is a different signal. Neither pattern is a reason to self-adjust the dose.
Blood counts: weeks, and only on a test
The trial in adults aged 70 to 95 saw red cell indices fall within 8 weeks at 1 mg daily.[7] Hemoglobin declined alongside them, and nobody in that trial reported symptoms from either change. For a reader, feeling well says nothing about whether the count moved.
Lipids and glucose: months, and silent
The metabolic cluster described in reviews of chronic use, raised triglycerides, cholesterol and glucose, produces no symptoms, so it surfaces on lab work rather than as a complaint.[4]
PEARL ran 48 weeks, which is the ceiling on what has been measured at weekly doses in healthy adults.[6] That is why the monitoring questions below lean on blood tests rather than on how anyone feels.
Which side effects only show up on a blood test?
Lipid, blood count and glucose changes produce no symptoms until advanced, and each is a routine blood test. A lipid panel, complete blood count, fasting glucose or HbA1c, plus liver and kidney function, before starting and periodically after, turns an unquantified risk into a monitored one.
What a closely monitored user reported
The most heavily tested public self-experimenter, Bryan Johnson, stopped taking the drug after several years across weekly, biweekly and alternating schedules, citing recurring skin infections, lipid and glucose problems and a higher resting heart rate that dose changes did not fix.
What the frequent labs caught
For a reader, the lesson is not that it harmed him. It is that frequent labs caught those signals, and that adjusting the dose is not a reliable way out.
- What this does not say:
- An n-of-1 account by a person who sells a longevity protocol, taking many other compounds at once; causation by rapamycin is his team's inference, not a controlled finding.
What to ask a prescriber before starting
The useful questions are about process rather than dose:
- Which baseline blood tests will be drawn, and when they will be repeated.
- How mouth ulcers, a fever or a slow-healing wound should be reported.
- Whether any current medication or supplement affects CYP3A4.
- What the plan is around surgery or a scheduled vaccine.
- Which lab result would prompt a pause, and who reviews the numbers when they arrive.
Which drugs interact with rapamycin, and who should avoid it?
Anything that shifts CYP3A4: strong inhibitors such as some antifungals, macrolide antibiotics and grapefruit juice raise sirolimus exposure sharply, while inducers such as certain anticonvulsants drop it. Live vaccines are generally avoided while dosing.
It is inappropriate in pregnancy or breastfeeding, around planned surgery, during active infection, and with poorly controlled diabetes or lung disease without specialist input. Read our guide to how prescribing and access actually work before assuming availability is the hard part.
What is a natural alternative to rapamycin?
There is no equivalent. Exercise, protein cycling and caloric restriction influence nutrient sensing, and marketed mimetics rest on weaker evidence. Our guide to what the natural alternatives can and cannot do covers them; none inhibits mTORC1 the way the drug does.
Is weekly low-dose rapamycin safe?
Not proven either way: at weekly doses in healthy adults, the common effects are mouth ulcers and mild stomach upset, and a 48-week trial did not find the metabolic derangement the transplant literature predicts. Calling the drug safe on that basis is the strongest false statement in this field.
What the reviews conclude
| Review | Question asked | What it found |
|---|---|---|
| Lancet Healthy Longevity, 2024 | How rapamycin and its derivatives have been used against aging in humans | 6 mg once a week was among the most common off-label regimens[13] |
| PEARL trial, 2025 | Safety of weekly dosing over 48 weeks in healthy adults | Adverse events broadly comparable to placebo[6] |
Nobody has run a multi-year study in healthy people, and current users are generating that data without controls or a registry. Our main guide to what rapamycin is and what the evidence shows covers the benefit side of the ledger.
Frequently asked questions
What should happen when mouth ulcers start?
Report them to the prescriber rather than changing the dose yourself. In pooled everolimus trials, 89% of first episodes appeared within 8 weeks and most were grade 1 or 2, so an early sore fits the expected pattern. A sore that recurs every cycle, or first appears months into a stable schedule, is a different signal.
How long has anyone been monitored on weekly doses?
48 weeks, in the PEARL trial, is the longest placebo-controlled record in healthy adults. Beyond that there is only self-reported use by individual self-experimenters, with no control group or registry.
Which blood tests go with low-dose rapamycin, and when?
A lipid panel, complete blood count, fasting glucose or HbA1c, and liver and kidney function, drawn before starting and repeated periodically. No trial has set a schedule for weekly dosing, and the one trial in adults aged 70 to 95 saw red cell indices fall within 8 weeks at 1 mg daily.
Does low-dose rapamycin have fewer side effects?
That is the premise, and the early human data supports tolerability rather than safety. The PEARL trial reported adverse events at 5 mg and 10 mg weekly broadly comparable to placebo across 48 weeks. Tolerable for 48 weeks in a small trial is not the same claim as safe for a decade, and nobody has run the decade.
Do supplements change how much rapamycin reaches the blood?
Some can. Sirolimus is cleared through CYP3A4, so any product that inhibits or induces that enzyme, grapefruit included, can shift exposure. A prescriber needs the full list of supplements, not only prescription drugs.
Can a normal blood panel rule out every side effect?
No. A panel catches lipid, glucose and blood count shifts, but not a rare infection or slow wound healing, which show up as events rather than numbers. That is why the reporting plan matters as much as the lab schedule.
Does rapamycin raise cholesterol?
At continuous immunosuppressive dosing, reliably. At weekly longevity dosing the 48-week data reported lipids staying inside normal ranges. That difference is exactly why lipids belong on a monitoring panel rather than being assumed harmless or assumed inevitable.
Can rapamycin affect blood counts?
Yes, and this is the effect you cannot feel. A trial of 1 mg daily in adults aged 70 to 95 found measurable declines in hemoglobin, red cell count and related indices over eight weeks, none clinically significant at that duration and none detectable without a complete blood count.
Does rapamycin interact with other drugs?
Extensively: sirolimus is metabolized by CYP3A4, so strong inhibitors such as some antifungals and macrolide antibiotics push exposure up, while inducers such as certain seizure medicines pull it down. Grapefruit juice belongs on the same list. A prescriber needs your full medication list before writing for it.
How long do rapamycin side effects last?
Sirolimus clears slowly, so effects tied to peak exposure fade across days rather than hours. Effects tied to cumulative exposure, lipids in particular, follow the overall schedule instead and resolve on the timescale of weeks after stopping.
References
10 sources, all link-checked; oldest check
- Rapamycin for longevity: the pros, the cons, and future perspectives. Roark KM, Iffland PH. Frontiers in Aging 2025;6:1628187.Peer-reviewed review, cited 31 times.Verified Sep 15, 2026
- Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Moel M et al. Aging (Albany NY) 2025;17(4):908–936.48-week RCT, 5/10 mg weekly; safe, no visceral-fat change; authors employed by AgelessRx; note conflict.Verified Sep 15, 2026
- A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort. Kraig E et al. Experimental Gerontology 2018;105:53–69.n=25, aged 70–95, 1 mg daily 8 weeks; tolerable, but measurable red-cell index changes.Verified Sep 15, 2026
- Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Rugo HS et al. Annals of Oncology 2016;27(3):519–525.Pooled data from seven phase 3 trials, the best quantification of mTOR-inhibitor stomatitis.Verified Sep 15, 2026
- mTOR inhibition improves immune function in the elderly. Mannick JB et al. Science Translational Medicine 2014;6(268):268ra179.RAD001 (rapalog) improved influenza-vaccine response ~20% in older adults.Verified Sep 15, 2026
- TORC1 inhibition enhances immune function and reduces infections in the elderly. Mannick JB et al. Science Translational Medicine 2018;10(449):eaaq1564.Phase 2a, n=264; significant reduction in reported infections over one year (p=0.001).Verified Sep 15, 2026
- Pharmacodynamic-guided dose-finding study of rapamycin in adult patients with solid tumors. Journal of Clinical Oncology, via PMC2654371.Maximum tolerated dose of DAILY oral rapamycin was 6 mg; toxicities in at least 20% of patients included hyperglycemia, hyperlipidemia and elevated transaminases.Verified Sep 15, 2026
- Sirolimus. Wikipedia.Verified Sep 15, 2026
- Rapamycin: one drug, many effects. Li J, Kim SG, Blenis J. Cell Metabolism 2014 (cited 1,631).Rapamycin acutely inhibits mTORC1, whereas chronic exposure can also inhibit mTORC2; this distinction underlies the intermittent dosing rationale in longevity use.Verified Sep 15, 2026
- Targeting aging with rapamycin and its derivatives in humans: a systematic review. Lee DJW et al. The Lancet Healthy Longevity 2024.Systematic review, cited 189 times.Publisher blocks automated checks · last tried Sep 15, 2026
Every link above is re-requested on a schedule by an automated checker; the date shown is when it last answered. Publishers that block automated requests are marked as such rather than reported broken. Our editorial standards explain how a source gets cited here in the first place.
Filed by the Rapamycin.store evidence desk. Each source is re-checked when the page is reviewed.
Own a longevity or health brand?
Rapamycin.store publishes sponsored and guest posts on an aged, topically-relevant domain, and offers display advertising. Tell us what you want to promote and we'll send our current options.